Opioid use disorder drug pipeline
- ICD-11 6C43
- MeSH D009293
1 compound from 1 company is in active clinical development for opioid use disorder.
- Phase 1/2 1
Mechanisms: Small molecule (1)
Pipeline data compiled July 2026 · every fact sourced.
Upcoming readouts & recent results
Larger confirmatory trial of BXCL501 in opioid withdrawal anticipated but not designed/scheduled as of Mar 2026. ↗
Investigator-sponsored Phase 1/2 (NCT05712707) topline: BXCL501 240 ug BID reduced opioid-withdrawal symptoms vs placebo (>30% SOWS-Gossop reduction) and numerically beat lofexidine with fewer adverse events. ↗
Compounds in development (1)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| Dexmedetomidine sublingual film (BXCL501) | BioXcel Therapeutics, Inc. | Phase 1/2 | Active | alpha-2A adrenoceptor Agonist |
Trials recruiting now (88)
88 drug-interventional opioid use disorder trials recruiting now, of 368 registered interventional trials. Browse all on ClinicalTrials.gov →
Buprenorphine (Experimental)
Buprenorphine, Oxycodone
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
- Phase 4Methadone Rapid Restart
Methadone
- Phase 4Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial
Naloxone Hydrochloride 0.4 MG/ML, Buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablet (2 mg/0.5 mg and 8 mg/2 mg), Buprenorphine extended-release injection (300 mg/1.5 mL)
Buprenorphine
Brixadi (Injectable Buprenorphine), Sublocade
Ketamine, standard general anesthesia
Extended-Release Buprenorphine (XRB), Sublingual Buprenorphine (SLB)
- Phase 4Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery
Buprenorphine Transdermal System, Placebo Patch
buprenorphine-naloxone
Showing the 12 most advanced of 88 recruiting drug trials · see all on ClinicalTrials.gov →
Frequently asked
- How many drugs are in development for opioid use disorder?
- 1 compound from 1 company is in active clinical development for opioid use disorder.
- What are the next opioid use disorder trial readouts?
- Upcoming catalysts include Dexmedetomidine sublingual film (BXCL501) (Date TBD).
- How many clinical trials are recruiting for opioid use disorder?
- 88 drug-interventional opioid use disorder trials are currently recruiting participants, out of 368 registered interventional trials.